Gliptin treatment tied to higher risk of acute pancreatitis

Gliptin treatment tied to higher risk of acute pancreatitis
(HealthDay)—Gliptin treatment is associated with increased acute pancreatitis risk, according to research published online Sept. 22 in Diabetes Care.

Ivan Tkac, M.D., Ph.D., from Pasteur University Hospital in Kosice, Slovakia, and Itamar Raz, M.D., from Hadassah Hebrew University Hospital in Jerusalem, combined data on the incidence of acute pancreatitis from three large randomized controlled trials designed to examine the and efficacy of add-on gliptin treatment. Data were included from SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin) for 18,238 gliptin-treated patients and 18,157 placebo-treated patients.

The researchers found that gliptin-treated patients had significantly increased incidence of acute pancreatitis (odds ratio, 1.79; P = 0.013). There was a small difference in absolute risk (0.13 percent).

"Treatment with gliptins significantly increased the risk for in a combined analysis of three large controlled randomized trials," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

Sitagliptin not linked to higher fracture risk in diabetes

More information: Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Gliptin treatment tied to higher risk of acute pancreatitis (2016, September 27) retrieved 21 March 2019 from https://medicalxpress.com/news/2016-09-gliptin-treatment-tied-higher-acute.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more